iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Tables)

Earnings (Loss) Per Common Share (Tables)

9 Months Ended

Mar. 31, 2020

Earnings (Loss) Per Common Share

Schedule of Earnings (loss) Per Share, Basic and Diluted


		Three Months Ended						Nine Months Ended
		March 31,						March 31,
		2020			2019			2020			2019
Basic and diluted numerator:

Net loss attributable to iBio, Inc.		$	(4,676)		$	(4,223)		$	(12,901)		$	(13,090)
Deemed dividends – down round of Series A Preferred and Series B Preferred			—			—			(21,560)			—
Preferred stock dividends – iBio CMO Preferred Tracking Stock			(65)			(64)			(196)			(195)
Net loss available to iBio, Inc. stockholders		$	(4,741)		$	(4,287)		$	(34,657)		$	(13,285)

Basic and diluted denominator:

Weighted-average common shares outstanding			79,917			19,224			47,018			18,597

Per share amount		$	(0.06)		$	(0.22)		$	(0.74)		$	(0.71)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share


		March 31,
		2020		2019
		(in thousands)
Stock options		2,158		947
Series A Preferred		—		4,980
Series B Preferred		28,925		6,428
Restricted stock units		41		—
Shares excluded from the calculation of diluted loss per share		31,124		12,355